Skip to main content
Premium Trial:

Request an Annual Quote

Axxam, Polyphor Team on Drug Screening

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Italian drug screening technologies company Axxam will collaborate with Swiss firm Polyphor on ion channel-based research, the firms said today.

The partners will use their respective drug discovery and screening platforms to identify drug candidates for therapeutic areas including pain, inflammation, and metabolic disorders.

Under the agreement, Axxam will provide its Hit Discovery platforms and capabilities and Polyphor will provide its screening technology and its knowledge in medicinal chemistry, drug discovery, and development. Polyphor's screening tools include the Protein Epitope Mimetics (PEM) technology, and it has built a PEM-based drug portfolio aimed at moving candidates through clinical trials.

"We believe that our unique cooperation and the complementary skill sets of both companies will offer a valuable alternative for innovation in the demanding field of ion channel based drugs and will industrialize the process for the generation of novel drugs for high medical needs," Axxam CEO and Chairman Stefan Lohmer said in a statement.

Axxam is situated in the San Raffaele Biomedical Science Park in Milan.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.